Detected ·
Alethio Therapeutics
$90MSeries A
Oxford spin-out Alethio Therapeutics raised an oversubscribed $90M (£67M) Series A, co-led by Sofinnova Partners and RA Capital Management, to advance its lead blood cancer programme ATX-011 toward Phase 3 readiness.
- Website
- www.alethiotherapeutics.com
- linkedin.com/company/76644628
- Amount
- $90 000 000 USD
- Stage
- Series A
- Event
- Funding round
- Detected
- 2026-11-05 20:17:44 UTC
- Signal ID
- bb599a87-18c9-488e-bed3-de9e37b5111c
As the API returns it
{
"id": "bb599a87-18c9-488e-bed3-de9e37b5111c",
"created_at": "2026-11-05T20:17:44.764076Z",
"company_name": "Alethio Therapeutics",
"company_website_url": "www.alethiotherapeutics.com",
"company_linkedin_url": "https://www.linkedin.com/company/76644628",
"event_type": "funding",
"funding_amount": 90000000,
"funding_currency": "USD",
"funding_stage": "series_a",
"message": "*Oxford spin-out Alethio Therapeutics raised an oversubscribed $90M (£67M) Series A, co-led by Sofinnova Partners and RA Capital Management, to advance its lead blood cancer programme ATX-011 toward Phase 3 readiness.*"
}